Page 5 - குழந்தைகள் புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail Research by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG. Affecting about 20 children in Australia each year, DIPG is a devastating disease with an average survival time of just nine months after diagnosis. The research, led by scientists at Children s Cancer Institute and published this week in the international journal, Cell Reports, offers an exciting new therapeutic approach for the treatment of DIPG by using a new anti-cancer drug. The new drug, CBL0137, is an anti-cancer compound developed from the antimalarial drug quinacrine. The researchers found that CBL0137 directly reverses the effects of the key genetic drivers in DIPG, and has a profound effect against DIPG tumour models. They also foundCBL0137 is even more effective when combined with a second drug, panobinostat, a new type of drug known as a histone deacetylase (HDAC) inhibitor. When used

New south walesDavid zieglerInstitute experimental therapeutics groupNational healthBenny wills brain tumour research fundGroup leader at children cancer instituteCancer instituteBrain tumours group at children cancer instituteKids cancer centreCure brain cancer foundationChildren cancer instituteResearch councilBrain tumours groupDiffuse intrinsic pontine gliomaCell reportsProfessor david ziegler